An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
Enrolling by invitation · NCT06549400 · Registry updated 2026-01-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Enrolling by invitation | Phase 3 | 2026-01-26 | NCT06549400 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lupin Atlantis Holdings S.A. | 4 |
| Lupin Ltd. | 5 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aarhus University Hospital | Aarhus | Denmark | 77 |
| Azienda Ospedaliera Universitaria Policlinico Tor Vergata | Rome | Italy | 4 |
| Laboratory for Muscle Diseases and Neuropathies | Leuven | Belgium | 2 |
| Ludug-Maximilians University | München | Germany | 2 |
| University College Hospital | London | United Kingdom | 9 |
| University Hospital of Madrid | Madrid | Spain | 2 |